Kendra Adams - Sep 18, 2023 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Chief Financial Officer
Signature: /s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol: CCCC
Transactions as of: Sep 18, 2023
Transactions value $: $0
Form type: 4
Date filed: 9/19/2023, 07:21 PM
Next filing: Feb 15, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Award	$0	+25K	+115.53%	$0.00	46.6K	Sep 18, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Stock Option (Right to Buy)	Award	$0	+111K		$0.00	111K	Sep 18, 2023	Common Stock	111K	$2.15	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on September 18, 2024, subject to the Reporting Person's continued service on each vesting date.
F2	25% of this option shall vest and become exercisable on September 18, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each vesting date.